#United States #Beverly Hills #Cellarity #GordonMD #Ted Myles

GordonMD Global Investments Appoints Ted Myles as New CEO of Cellarity

In a significant move for the life sciences sector, GordonMD Global Investments® has announced the appointment of Ted Myles as the new Chief Executive Officer of Cellarity. This strategic decision comes at a crucial time as Cellarity accelerates towards its first clinical trial, greatly supported by the guidance and investments from GordonMD Global Investments.

Cellarity is a pioneering company in the biopharmaceutical space that is revolutionizing traditional methods of drug creation. Ted Myles brings over two decades of invaluable experience within the biopharma industry, having honed his expertise in both clinical and commercial settings. His track record is impressive, accentuated by roles as CFO and COO at notable companies such as Scholar Rock, where he helped navigate the organization through critical phases, including its successful Phase 3 registrational study.

Craig Gordon, M.D., the founder and CEO of GordonMD, expressed his enthusiasm for Myles' appointment. He emphasized the opportune moment for Myles to lead Cellarity, as the company stands ready to leverage its innovative drug creation platform to discover new treatments for diseases that currently lack effective therapies. A prime example of this innovative approach is Cellarity's upcoming clinical trial focused on sickle cell disease, showcasing their commitment to addressing significant medical needs.

In response to his new role, Ted Myles articulated his exaltation about leading Cellarity, highlighting the company's unique AI-powered platform and its scientific vision. He expressed gratitude towards Craig Gordon and GordonMD for their steadfast belief in Cellarity’s mission, affirming his excitement about guiding the talented team as they work towards clinical development and expansion into new disease areas.

Cellarity's lead program, designated CLY-124, is set to be a potential first-in-class small molecule aimed at treating sickle cell disease. By manipulating fetal hemoglobin through a novel target uncovered via Cellarity’s innovative platform, CLY-124 is anticipated to begin clinical development by mid-2025.

The appointment of Ted Myles signifies not just a change in leadership but also a reinforcement of Cellarity's mission to generate groundbreaking treatments in the healthcare landscape, one that holds endless possibilities for patients suffering from debilitating diseases. As the company seems poised for its pivotal clinical trials, industry observers and stakeholders alike are keenly watching how Myles' leadership will shape Cellarity's future in the biopharmaceutical field.

As GordonMD Global Investments continues to support biopharmaceutical enterprises across the U.S., Europe, and Asia, the alignment of their vision with Cellarity's innovative pathways sets the stage for transformative advancements in medicine. This appointment is a clear testament to the pressing need for continued evolution and investment in life sciences, as the hunt for effective therapies intensifies in an ever-competitive landscape.